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Sixteen new isothiazoloisoxazole 1,1-dioxides, one new isothiazolotriazole and one new 
isothiazolopyrazole have been synthesised by using 1,3-dipolar cycloadditions to isothiazole 
1,1-dioxides. One sub-set of these isothiazoloisoxazoles showed low μM activity against a 
human breast carcinoma cell line, whilst a second sub-set plus the isothiazolotriazole 
demonstrated an interesting restricted rotation of sterically hindered bridgehead substituents. A 
thiazete 1,1-dioxide produced from one of the isothiazole 1,1-dioxides underwent conversion 
into an unknown 1,2,3-oxathiazolin-2-oxide upon treatment with Lewis acids, but was inert 
towards 1,3-dipoles and cyclopropenones. Six supporting crystal structures are included.   
 
 
 
Introduction 
Four-membered heterocyclic rings containing one nitrogen 
atom are well known within organic chemistry. The field is 
dominated by the β-lactams (1) [Figure 1] due to the 
importance that they have acquired as anti-infective agents.1-3 
The corresponding β-sultams (2) are also known and have 
attracted attention as taurine precursors,4,5 β-lactamase 
inhibitors,6 D,D-peptidase inhibitors,7 human neutrophil elastase 
inhibitors,8-10 azoreductase inhibitors,11 anti-inflammatory 
agents,12 potential treatments for alcohol dependency,13 SPase I 
inhibitors14 and ClpP protease inhibitors,15 and have attracted 
other mechanistic16,17 and synthetic efforts.18-20 β-Sultam 
chemistry been a focus of our research for some time.6-10,12,13,17 
 
Figure 1. Heterocycles of interest in this work 
 
Our interest in four-membered ring nitrogen heterocycles has 
also included the study of the chemistry of the unsaturated 1-
azetine (3),21-24 a system that is easily accessed from β-lactams, 
although the 1-azetine remains a heterocycle that attracts very 
little attention.25 Nonetheless, we have shown that 1-azetines 
are able to act as precursors for the synthesis of 
benzoisoquinolines,21 homotropane related heterocycles22 and 
pyridines23 via a formal [3+2]-cycloaddition reaction with 
cyclopropenones (which act as all-carbon 1,3-dipole 
equivalents) as well as acting as dipolarophiles for the synthesis 
of 1,2,4-oxadiazoles24 via reaction with nitrile oxides. As a 
result of these successes, and given our interest in the β-sultam 
nucleus, we wished to explore the chemistry of the unsaturated 
β-sultam system, the thiazete 1,1-dioxide (4). In parallel with 
our studies on the 1-azetine heterocycle, we anticipated that the 
thiazete 1,1-dioxide nucleus would be a suitable precursor for 
cyclopropenone based [3+2]-cycloaddition processes and 1,3-
dipolar cycloadditions, thus providing access to novel bicyclic 
β-sultams. We were particularly attracted to the thiazete 1,1-
dioxide (5a) that was produced by Clerici and co-workers26 via 
ring contraction of an isothiazole 1,1-dioxide (6a) and by the 
under-explored and appealing nature of the chemistry that leads 
to this 4-membered unsaturated heterocycle.             
 
Results and discussion 
 
Synthesis and Reactivity of Isothiazole 1,1-dioxides and 
Thiazete 1,1-dioxides 
We synthesised the thiazete 1,1-dioxide (5a)26 from the 
precursor isothiazole 1,1-dioxide (6a) by adapting the route 
described by Clerici27 as shown in Scheme 1. Thus, 
dibromination of an enone precursor gave a mixture of dibromo 
compounds (7a, Ar = 4-MeOC6H4) which was reacted with 
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diethylamine to give intermediate (8a, Ar = 4-MeOC6H4, R = 
Et, 81% yield) as an isolable, adequately characterised but, in 
our hands, rapidly degrading intermediate. 
 
 
Scheme 1. Synthesis and reactivity of thiazete 1,1-dioxide (5) 
 
Treatment of compound (8a) with methanesulfonyl azide 
initiates a reaction27 whereupon the alkene undergoes a 1,3-
dipolar cycloaddition followed by loss of phenyldiazomethane 
to give an 82% yield of the pure N-methanesulfonylamidine 
(9a, Ar = 4-MeOC6H4, R = Et). Cyclisation of compound (9a) 
with t-butoxide in THF gave the alcohol (10a, Ar = 4-
MeOC6H4, R = Et, 89%). The alcohol was converted into the 
corresponding tertiary chloride (11a) which formed in 95% 
yield together with 4% of the dichloro compound (12a). 
Elimination of HCl from compound (11a) gave an 86% yield of 
the isothiazole 1,1-dioxide (13a, Ar = 4-MeOC6H4, R = Et), 
whilst elimination of HCl from the dichloro compound 12a 
gave the 5-chloroisothiazole 1,1-dioxide (14a). The isothiazole 
1,1-dioxide (13a) was converted (93% yield) into the 5-
bromoisothiazole 1,1-dioxide (15a) and thence to the 5-
methanesulfonylisothiazole 1,1-dioxide (6a, Ar = 4-MeOC6H4, 
R = Et) via the 5-methanesulfanyl26,28 and sulfoxide 
intermediates (16a) and (17a), in 97% and 67% yields, 
respectively. We were able to convert the chloro compound 
(14a) into the methanesulfanyl derivative (16a) but never 
reached the 97% yield achieved with the bromo derivative 
(15a). Direct oxidation of compound (16a) into (6a) was also 
found to be convenient, albeit in a reduced single step yield of 
51%. When 5-methanesulfonyl-isothiazole 1,1-dioxide (6a) 
was treated with sodium azide in acetonitrile it underwent the 
expected26 but remarkable ring contraction (see later for a 
mechanistic discussion) to furnish the desired thiazete 1,1-
dioxide (5a, Ar = Ar = 4-MeOC6H4, R = Et). 
We attempted the reaction of the thiazete 1,1-dioxide (5a) with 
nitrile oxides  and cyclopropenones (19) in order to form 
cycloadducts (18) and (20), illustrated in Scheme 1. No 
reactions of the imine present in the thiazete 1,1-dioxide (5a) 
were observed, and the starting material was returned 
unchanged in all cases, a huge disappointment given that we 
had shown that the imine within the 1-azetine system reacts 
easily with both nitrile oxides and cyclopropenones.21-24 Other 
1,3-dipoles (nitrile ylides, nitrilimines, nitrones, aryl azides and 
azomethine ylides) and dienes were found to be similarly 
unreactive. Interestingly, when the cyclopropenone reaction 
was attempted in the presence of a Lewis acid, a reaction was 
observed. On these occasions, the product was found to be the 
previously unreported 1,2,3-oxathiazolin-2-oxide (21 – see 
Scheme 1), the product of a hitherto unknown rearrangement of 
the thiazete 1,1-dioxide (5). This product was also obtained in 
the absence of the cyclopropenone. Compound (21) was 
typically formed as a ~2.5:1 mixture of diastereoisomers with 
the major diastereoisomer isolated in a maximum yield of 31% 
yield using zinc chloride as the Lewis acid, and for which we 
were unable to determine the relative stereochemistry. A 
possible mechanism for the formation of compound (21) from 
(5) is shown in Scheme 2, based upon a known rearrangement 
of simple (saturated) 3-aryl β-sultams into simple (saturated) 
1,2,3-oxathiazolidines.29 
 
 
Scheme 2. Mechanism for formation of 1,2,3-oxathiazolin-2-oxide (21) 
 
Disappointed by the inert nature of thiazete 1,1-dioxide (5a) 
towards 1,3-dipoles and cyclopropenones, we next investigated 
the reactivity of isothiazole 1,1-dioxides (10a – 17a) and (6a, 
Ar = 4-MeOC6H4, R = Et). No reactivity was observed from 
any of these compounds towards cyclopropenones. Compounds 
(10a – 12a) were also unreactive towards 1,3-dipoles. 
However, compounds (13a – 15a), (17a) and (6a) [Ar = 4-
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MeOC6H4, R = Et] were reactive towards a series of five nitrile 
oxides, forming a series of isothiazoloisoxazoles (22) as shown 
in Scheme 3 and Table 1 (entries a – i). It is of note that we 
found the thioether compound (16a) (entry j, Table 1) to be 
unreactive, possibly due to the electron donating nature of this 
substituent when compared to the other isothiazole 1,1-dioxides 
used. The reactivity of compound (13a) towards nitrile oxides 
has also been investigated by Clerici (see below).30 
It is of note that all of the reactions were regioselective and 
diastereoselective, giving the syn-diastereoisomer shown in 
Scheme 3. The observed regiochemistry is predictable on the 
basis of the alkene polarity and was apparent from HMBC 
spectra. The syn-diastereoselectivity is explained by the 
concerted nature of the cycloaddition. The stereochemistry was 
apparent from NOESY spectra and other NMR studies (see 
below). We were also able to confirm the structures of 
compounds (22a), (22h) [both diastereoisomers] and (22i) by 
X-ray crystallographic studies.31  
We next decided to extend the scope of this reaction and 
produced a range of five additional isothiazole 1,1-dioxides 
(13b - f) (as shown in Table 2), four of which (13b, c, d and f) 
are previously unreported and were produced using the route 
described in Scheme 1 in the yields shown in Table 2. In 
general, the chemistry proceeded without incident. However, all 
attempts to obtain pure samples of intermediate (8b – f) were 
unsuccessful. Fortunately, we found that the crude mixtures 
could be treated with methanesulfonyl azide whereupon the 
pure N-methanesulfonylamidines (9b - f) could be isolated in 
reasonable yields (see Table 2). There is great interest in azide 
to alkene 1,3-dipolar cycloaddition chemistry,32-37 so we were 
particularly pleased to see that the key 1,3-dipolar 
cycloaddition/1,3-dipolar cycloreversion based conversion of 
compounds (8b – f) into (9b – f) showed itself to be repeatable 
and reliable even with crude starting material. Conversion of 
compounds (9b – f) into heterocycles (13b – f, see Table 2 for 
Ar and R) proceeded without further issues. Isothiazole 1,1-
dioxides (13b - f) were reacted with nitrile oxides to give the 
isothiazoloisoxazoles (22k – t), again as single regio- and syn-
diastereoisomers, as shown in Table 1.  
It is important to note that Clerici and co-workers have reported 
the synthesis of a library of six isothiazoloisoxazoles accessed 
from one of these isothiazole 1,1-dioxides (13a, Ar = 4-
MeOC6H4, R = Et)
30 and six nitrile oxides as well as two 
further adducts isolated from the reactions of 3-benzylamino-
isothiazole 1,1-dioxide38 (not studied in our work). However, 
only 3 of the 19 compounds reported in Table 1 (compounds 
22a, 22d and 22e) have been reported previously, and our work 
has demonstrated that this chemistry is more widely applicable 
than reported previously, both in terms of precursor (13) 
synthesis and adducts (22) produced.  
 
Scheme 3. Synthesis of isothiazoloisoxazoles (22) [see Table 1] 
 
Table 1. Scope of isothiazoloisoxazole structures (22) [see Scheme 3] 
 
Entry Ar Y R R1 Yield 
(22)  
(%) 
22a 4-MeOC6H4 H Et CO2Et 86 
22b 4-MeOC6H4 H Et C6H5 71 
22c 4-MeOC6H4 H Et 2-N3C6H4 62 
22d 4-MeOC6H4 H Et 4-NO2C6H4 42 
22e 4-MeOC6H4 H Et 4-MeOC6H4 71 
22f 4-MeOC6H4 Cl Et 4-MeOC6H4 56 
22g 4-MeOC6H4 Br Et 4-MeOC6H4 54 
22h 4-MeOC6H4 SOMe Et 4-MeOC6H4 52 
22i 4-MeOC6H4 SO2Me Et 4-MeOC6H4 68 
22j 4-MeOC6H4 SMe Et 4-MeOC6H4 0 
22k 4-MeOC6H4 H n-Pr 4-MeOC6H4 29 
22l 4-MeOC6H4 H n-Pr 4-ClC6H4 30 
22m 4-ClC6H4 H Et 4-ClC6H4 51 
22n 4-ClC6H4 H Et 4-MeOC6H4 45 
22o 4-ClC6H4 H n-Pr 4-MeOC6H4 25 
22p 4-ClC6H4 H n-Pr 4-ClC6H4 29 
22q 4-MeC6H4 H Et 4-MeOC6H4 39 
22r 4-MeC6H4 H Et 4-ClC6H4 41 
22s 4-MeC6H4 H (CH2)5 4-MeOC6H4 54 
22t 4-MeC6H4 H (CH2)5 4-ClC6H4 28 
 
Table 2. Range of isothiazole 1,1-dioxides (13) [see Scheme 1] 
 
Entry Ar R Yield 
(13) 
(%) 
Yield 
(11) 
(%) 
Yield 
(10) 
(%) 
Yield (9) 
[from (7)] 
(%) 
b 4-MeOC6H4 n-Pr 76 97 99 80 
c 4-ClC6H4 Et 79 82 83 53 
d 4-ClC6H4 n-Pr 97 85 76 75 
e 4-MeC6H4 Et 30 66 77 29 
f 4-MeC6H4 (CH2)5 62 71 42 54 
 
Given that compound (6a) underwent the ring contraction to 
give thiazete (5a) upon treatment with sodium azide, we also 
explored the reactivity of compounds (14a – 17a, Ar = 4-
MeOC6H4, R = Et) towards sodium azide. Only compound 
(17a) showed a reaction and in this case we were able to isolate 
the previously unreported isothiazolotriazole cycloadducts (23a 
and b) [Scheme 4] as a ~5:6 mixture of diastereoisomers in a 
combined yield of 49% [we confirmed the structure of the 
major diastereoisomer by X-ray crystallography31]. Clerici and 
co-workers also isolated an isothiazolotriazole when exploring 
the reactivity of isothiazole 1,1-dioxide (13a, Ar = 4-MeOC6H4, 
R = Et) towards sodium azide.39 Together, these observations 
suggest that the ring contraction mechanism for the addition of 
sodium azide to isothiazole 1,1-dioxide (6a) to give the thiazete 
1,1-dioxide (5a) may proceed via an isothiazolotriazole 
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intermediate (as shown in Scheme 4) which, in the case of the 
sulfone, collapses to give the ring-contracted final product due 
to enhanced stability of the sulfone leaving group versus the 
sulfoxide leaving group. Finally, also shown in Scheme 4, we 
reacted the isothiazole 1,1-dioxide (13a) with a nitrilimine to 
give adduct (24, Ar = 4-MeOC6H4, R = Et) in 41% yield, a 
structure that we confirmed by X-ray crystallographic studies.31 
Attempted reaction with other nitrilium betaines (nitrile ylides 
and nitrile sulfides) was not fruitful, although adducts of 
isothiazole 1,1-dioxide (13a) with Münchnones, diazo 
compounds and aryl azides have been reported.40-42 
 
Scheme 4. Synthesis of azide and nitrilimine adducts (23) and (24) [Ar 
= 4-MeOC6H4, R = Et] 
 
Conformational Studies of Isothiazoloisoxazoles 
 
The NMR spectra of the previously unreported cycloadducts 
(22f – i, Figure 2) revealed some unexpected results. For 
compounds (22f) and (22g), the two pairs of aromatic protons 
on the bridgehead aryl group were expected to give two 
doublets in the 1H NMR spectra integrating to two protons 
each. Instead, these protons appeared as two broad signals in a 
1:3 ratio, indicating that they are in different electronic 
environments due, we assume, to a restricted rotation of the 
aromatic ring on the ring junction. 
For compound (22h), formed as a separable mixture of 
diastereoisomers, the aromatic protons of the bridgehead aryl 
group appeared as four distinct (albeit overlapping) signals 
which were broad for one isomer but resolved for the other. For 
compound (22i) the broadening of the signals in the 1H NMR 
spectrum disappeared and the four aromatic protons of the 
bridgehead aryl group gave four very distinctive doublets of 
doublets. These results also indicate a restricted rotation of the 
aromatic ring and a different electronic environment for each 
proton. 
In the 13C NMR spectra for compounds (22f) and (22g), two 
flattened but distinct peaks appeared for the two aromatic CH 
carbons closer to the stereogenic centre at the ring junction, 
whereas no discrimination was observed between the two other 
aromatic CH carbons, i.e. those ortho to the methoxy group on 
the bridgehead aryl group. For the two diastereoisomers of 
compound (22h) and for compound (22i), the four aromatic CH 
carbons on the ring junction aryl group appeared as separate 
signals. These observations again indicate that the aromatic CH 
carbons on the ring junction aryl ring are in different 
environments, providing further evidence of the restriction of 
the rotation of the aromatic ring. Steric hindrance between the 
bridgehead aryl group and the substituent Y across a syn-ring 
junction as shown in Figure 2 would account for the restricted 
rotation of the aromatic ring. 
 
Figure 2 Restricted rotation of the bridgehead aryl group  
 
The broadening of the signals for the aromatic protons in the 1H 
NMR spectra decreases in the order Cl < Br < SOMe < SO2Me. 
The larger the substituent, the smaller the amplitude of the 
rotation, which then allows a more defined electronic 
environment,43 and a more resolved signal. 
This phenomenon also accounts for the intact AB system that is 
observed in those examples of adducts (22) where Y = H in 
which there is free rotation of the aromatic ring at the ring 
junction due to minimal steric hindrance. In these cases, the two 
aromatic protons in each proton pair are in the same 
environment and appear as the expected two doublets. 
In the 13C NMR spectra of compounds (22f) and (22g), efficient 
relaxation and environmental exchange accounts for the 
observed flattening, broadening and coalescence of some 
signals.43 For compounds (22h) and (22i), the presence of four 
aromatic CH carbon signals for the bridgehead aryl group is 
due to the increasingly restricted rotation of the aromatic ring at 
the ring junction. In those systems with Y = H, rotation is not 
restricted and only two CH environments are observed for the 
bridgehead aryl group. 
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Compounds (23a/b) – with only one aryl ring – exhibited the 
same phenomena, with the presence of four CH signals in the 
aromatic region of the 13C NMR spectrum for each 
diastereoisomer and the presence of four non-equivalent 
aromatic protons (with some overlap) in the 1H NMR spectra.   
 
Antiproliferative Activity of Isothiazoloisoxazoles 
 
Whilst the biological activity of monocyclic isothiazole 
dioxides as protein farnesyltransferase inhibitors44,45 and 
antiproliferatives45,46  has been established, we are aware of no 
reports dealing with bicyclic systems. Thus, we investigated the 
activity of a subset of the isothiazoloisoxazoles as 
antiproliferative agents. Compounds (22k), (22m), (22o) and 
(22p) had suitable solubility in DMSO and were tested for 
cytotoxicity against human breast carcinoma cell line, MCF-7 
cells. IC50 values are shown in Table 3. Compound (22o) only 
showed inhibition of cell growth after 96 hours of incubation 
whereas compounds (22k), (22m) and (22p) showed inhibition 
at 48 and 72 hours. Compound (22m) showed the greatest 
activity, and work is currently underway in our laboratories to 
discover derivatives with nM levels of activity.  
 
Table 3. IC50 values for isothiazoloisoxazoles against MCF-7 cells 
 
Compound IC50 μM (48 hr) IC50 μM (72 hr) IC50 μM (96 hr) 
22k 8.50 6.25 3.75 
22m 3.10 3.75 1.50 
22o - - 5.50 
22p 8.25 5.50 6.50 
 
 
Experimental 
General Considerations 
 
All reactions were monitored and analysed by TLC using 
Macherey-Nagel 0.2 mm pre-coated Alugram® N/UV254 silica 
gel or alumina gel plates. Column chromatography was 
conducted using 60 Å, 70 – 230 mesh, 63 – 200 μm silica gel 
supplied by Sigma-Aldrich. Petroleum ether (PE) refers to the 
fraction boiling at 40 – 60 °C. Where necessary, 60Å, 50 – 200 
μm, basic alumina gel was used and was supplied by Acros. 
Analysis by NMR spectroscopy was achieved using Bruker 
DPX, Bruker AVIII 400 MHz NMR and Bruker AV500 NMR 
spectrometers. Analysis by high resolution mass spectrometry 
was achieved using a Bruker Daltonics micrOTOF-Q Mass 
Spectrometer. Infra-red analysis was achieved using a Nicolet 
380 FT-IR spectrometer and samples were run as neat oils or 
solids. Melting point determinations were made using a Stuart, 
SMP10 digital melting point apparatus. X-ray crystallographic 
information is given in the Supplementary Information.  
 
MCF-7 cells, human breast carcinoma cell line (American Type 
Culture Collection) were grown and maintained in RPMI 1640 
medium supplemented with 10% fetal bovine serum at 37 °C, 5% 
CO2. The cells were plated in 96-well culture plates at a density of 1 
× 104 cells/well and allowed to adhere at 37 °C for 24 hours. The 
following day, various doses of the compounds were added to the 
cells and further incubated for 24 h, 48 h, 72 h or 96 h.  The 
supernatant was removed and MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide)  was added for 4 hours. The 
ability of cells to form formazan crystals by active mitochondrial 
respiration was determined by using a Microplate reader after 
dissolving the crystals in DMSO. Cytotoxicity was expressed as a 
relative percentage of the absorbance measured at 540 nm in the 
control and extract-treated cells. Data were determined as the mean 
± s.e. mean for 4 separate experiments of 8 readings for each dose. 
Compounds 5a and 6a,26 8a, 8e, 9a, 9e, 10a, 10e, 11a, 11e, 13a and 
13e,27 15a,47 16a,28 and 22a, 22d and 22e30 have been reported 
previously, although only compounds 5a, 6a and 15a had full 
spectroscopic characterisation data (including 13C NMR data) 
reported. Thus, full characterisation data and improved procedures 
for the synthesis of these compounds can be found in the Supporting 
Information. Other compounds are previously unreported. 
Representative procedures and data appear below for compounds 8, 
9b, 10b, 11b, 13b, 14a, 17a, 21, 22b, 22f – i, 23a/b and 24. Data 
and procedures for compounds 9c, d and f, 10c, d and f, 11c, d and f, 
13c, d and f, 22c and 22k – t are detailed in the Supporting 
Information.  
2-(Alkylamino)-1-aryl-3-phenyl-prop-2-en-1-ones (8b – 8d, 8f) 
 
To the 2,3-dibromo-1-aryl-3-phenyl-propan-1-one (7) (4.5 – 5.0 
g, 11.4 – 12.6 mmol) stirring in ethanol (10 – 40 mL) at room 
temperature under an atmosphere of nitrogen was added the 
amine (2 equivalents, 22.8 – 25.2 mmol) and the mixture 
allowed to stir for 24 hours. After this time sodium ethoxide (1 
equivalent, 11.4 – 12.6 mmol) was added and the reaction 
mixture was stirred for a further 24 hours. Solvents were then 
removed under reduced pressure and the residues were 
dissolved in dichloromethane. The solution was filtered to 
remove sodium bromide and the filtrate was concentrated under 
reduced pressure. The crude products were taken to the next 
stage without further purification or analysis. 
 
2-(4-Methoxyphenyl)-N'-methylsulfonyl-2-oxo-N,N-
dipropyl-acetamidine (9b) 
 
Under an atmosphere of nitrogen, a solution of the 2-
(dipropylamino)-1-(4-methoxyphenyl)-3-phenyl-prop-2-en-1-
one (8b) crude reaction mass (12.56 mmol based upon 7a, 5.0 
g) in ethanol (45 mL) was added to a solution of 
methanesulfonyl azide (1.79 g, 14.80 mmol) in ethanol (15 
mL). The reaction mixture was set to stir at reflux for 24 hours. 
After this time, solvents were removed under reduced pressure. 
The crude product was purified by gravity silica column 
chromatography with a 1:1 petroleum ether:ethyl acetate 
solvent system to yield the pure product as an orange oil (3.40 
g, 80%). 
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1H NMR δ (400 MHz, CDCl3): 0.73 (3H, t, J = 7.4 Hz, 
NCH2CH2CH3); 1.01 (3H, t, J = 7.4 Hz, NCH2CH2CH3); 1.41 
– 1.69 (2H, m, NCH2CH2CH3); 1.72 – 1.87 (2H, m, 
NCH2CH2CH3); 2.96 (3H, s, SO2CH3); 2.98 – 3.10 (2H, m, 
NCH2CH2CH3); 3.35 – 3.44 (1H, m, NCH2CH2CH3); 3.61 – 
3.71 (1H, m, NCH2CH2CH3); 3.89 (3H, s, ArOCH3); 7.00 (2H, 
d, J = 7.8 Hz, ArH); 7.86 (2H, d, J = 7.8 Hz, ArH). 
13C NMR δ (100 MHz, CDCl3): 10.94 (NCH2CH2CH3), 11.47 
(NCH2CH2CH3), 19.90 (NCH2CH2CH3), 21.72 
(NCH2CH2CH3), 42.60 (SO2CH3), 49.53 (NCH2CH2CH3), 
51.36 (NCH2CH2CH3), 55.70 (ArOCH3), 114.57 (Ar), 127.69 
(Ar), 131.36 (Ar), 162.68 (Ar), 164.88 (N=C-N), 171.15 
(C=O). 
IR (cm-1): 833.5, 959.6, 1015.8, 1128.7, 1168.9, 1234.5, 
1258.9, 1291.2, 1541.6, 1596.4. 
micrOTOF-Q MS m/z C16H24N2O4S+Na, calculated 363.1349, 
observed 363.1348. 
 
 
3-(Dipropylamino)-4-(4-methoxyphenyl)-1,1-dioxo-5H-
isothiazol-4-ol (10b)   
 
To 2-(4-methoxyphenyl)-N'-methylsulfonyl-2-oxo-N,N-
dipropyl-acetamidine (9b) (3.40 g, 9.98 mmol) in dry 
tetrahydrofuran (12 mL) under an atmosphere of nitrogen, a 
20% w/v solution of potassium t-butoxide in tetrahydrofuran 
(6.00 mL, 9.98 mmol) was added rapidly at room temperature 
and the reaction mixture set to stir for 24 hours. After this time, 
the reaction mixture was neutralised with 1M hydrochloric 
acid. The aqueous mixture was extracted with dichloromethane 
(3 × 25 mL) and the organic layers combined and washed with 
water. The organics were dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure to 
yield the product as a yellow oil (3.35 g, 99%) which was used 
directly in the next step.  
 
1H NMR δ (400 MHz, CDCl3): 0.60 (3H, t, J = 7.3 Hz, 
NCH2CH2CH3); 0.87 – 0.96 (4H, m, NCH2CH2CH3, 
NCH2CH2CH3); 1.40 – 1.51 (1H, m, NCH2CH2CH3); 1.57 – 
1.80 (2H, m, NCH2CH2CH3); 3.14 – 3.16 (2H, m, 
NCH2CH2CH3); 3.34 – 3.35 (2H, m, NCH2CH2CH3); 3.62 (1H, 
d, J = 14.1 Hz, SO2CH2); 3.82 (3H, s, ArOCH3); 3.89 (1H, d, J 
= 14.0 Hz, SO2CH2); 5.52 – 5.89 (1H, broad, OH); 6.91 (2H, d, 
J = 8.9 Hz, ArH); 7.45 (2H, d, J = 8.9 Hz, ArH). 
13C NMR δ (100 MHz, CDCl3): 10.88 (CH3), 11.29 (CH3), 
19.29 (CH2), 21.01 (CH2), 50.62 (NCH2), 52.15 (NCH2), 55.36 
(ArOCH3), 64.62 (SO2CH2), 83.54 (COH), 114.31 (Ar), 125.28 
(Ar), 133.03 (Ar), 159.52 (Ar), 169.02 (N=C-N). 
IR (cm-1): 834.9, 857.6, 913.6, 1033.0, 1127.9, 1147.7, 1229.8, 
1264.7, 1513.5, 1581.8. 
micrOTOF-Q MS m/z C16H24N2O4S+Na, calculated 363.1349, 
observed 363.1340. 
 
 
 
4-Chloro-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-5H-
isothiazol-3-amine (11b)  
 
Under an atmosphere of nitrogen, thionyl chloride (6.38 mL, 
87.90 mmol) was added to 3-(dipropylamino)-4-(4-
methoxyphenyl)-1,1-dioxo-5H-isothiazol-4-ol (10b) (1.00 g, 
2.93 mmol) and the mixture set to stir at reflux for 24 hours. 
After this time the excess thionyl chloride was removed under 
reduced pressure. The residues were then dissolved in 
dichloromethane and neutralised with 10% w/v aqueous sodium 
bicarbonate solution. The aqueous layer was removed and 
extracted with dichloromethane (3 × 25 mL) and the organic 
layers combined and washed with water. The organics were 
dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude product was 
purified by gravity silica column chromatography (2:1 
PE:EtOAc) to yield the pure product as a yellow oil (1.06 g, 
97%). 
 
1H NMR δ (400 MHz, CDCl3): 0.57 (3H, t, J = 7.4 Hz, 
NCH2CH2CH3); 0.95 (3H, t, J = 7.4 Hz, NCH2CH2CH3); 1.00 
– 1.14 (1H, m, NCH2CH2CH3); 1.45 – 4.60 (1H, m, 
NCH2CH2CH3); 1.61 – 1.87 (2H, m, CH2CH2CH3); 2.89 – 3.08 
(2H, m, NCH2CH2CH3); 3.35 – 3.44 (1H, m, NCH2CH2CH3); 
3.47 – 3.56 (1H, m, NCH2CH2CH3); 3.81 (1H, d, J = 14.6 Hz, 
SO2CH2); 3.84 (3H, s, ArOCH3); 4.16 (1H, d, J = 14.6 Hz, 
SO2CH2); 6.95 (2H, d, J = 9.0 Hz, ArH); 7.42 (2H, d, J = 8.9 
Hz, ArH). 
13C NMR δ (100 MHz, CDCl3): 10.84 (CH3), 11.24 (CH3), 
19.12 (CH2), 20.68 (CH2), 51.21 (NCH2), 52.22 (NCH2), 55.51 
(ArOCH3), 67.98 (SO2CH2), 71.22 (COH), 114.75 (Ar), 126.15 
(Ar), 130.48 (Ar), 160.15 (Ar), 164.87 (N=C-N). 
IR (cm-1): 832.0, 911.9, 1027.2, 1139.8, 1237.0, 1255.1, 
1313.3, 1509.6, 1577.3, 2964.5. 
micrOTOF-Q MS m/z C16H23ClN2O3S+Na, calculated 
381.1010, observed 381.1011. 
 
 
4-(4-Methoxyphenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine 
(13b) 
 
To 4-chloro-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-5H-
isothiazol-3-amine (11b) (3.72 g, 10.34 mmol) in dry acetone 
(50 mL) under an atmosphere of nitrogen, anhydrous potassium 
carbonate (1.57 g, 11.37 mmol) was added and the reaction 
mixture set to stir at reflux for 24 hours. After this time the 
mixture was filtered to remove excess potassium carbonate and 
the solvents removed under reduced pressure. The residues 
were dissolved in dichloromethane and neutralised with 1M 
aqueous hydrochloric acid. The aqueous layer was removed and 
extracted with dichloromethane (3 × 25 mL) and the organic 
layers combined and washed with water. The organics were 
dried over anhydrous magnesium sulfate, filtered and 
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concentrated under reduced pressure to yield the product as a 
brown oil (3.30 g, 76%) which was a single spot by TLC and 
did not need to be purified further. 
 
1H NMR δ (400 MHz, CDCl3): 0.43 (3H, t, J = 7.2 Hz, 
NCH2CH2CH3); 0.95 (3H, t, J = 7.2 Hz, NCH2CH2CH3); 1.32 
– 1.44 (2H, m, NCH2CH2CH3); 1.70 – 1.83 (2H, m, 
NCH2CH2CH3); 2.98 (2H, t, J = 7.8 Hz, NCH2CH2CH3); 3.52 
(2H, t, J = 7.6 Hz, NCH2CH2CH3); 3.85 (3H, s, ArOCH3); 6.97 
(2H, d, J = 8.8 Hz, ArH); 7.17 (1H, s, SO2CH); 7.23 (2H, d, J 
= 8.8 Hz, ArH). 
13C NMR δ (100 MHz, CDCl3): 10.51 (CH3), 11.36 (CH3), 
19.98 (CH2), 22.62 (CH2), 51.45 (NCH2), 54.29 (NCH2), 55.49 
(ArOCH3), 114.59 (Ar), 123.86 (Ar), 128.70 (Ar), 139.69 (Ar), 
143.05 (SO2CH), 160.57 (C=C-Ar), 161.31 (N=C-N). 
IR (cm-1): 733.4, 835.6, 1027.7, 1123.2, 1189.2, 1249.4, 
1290.9, 1506.6, 1556.2, 1603.9, 3102.9. 
micrOTOF-Q MS m/z C16H22N2O3S+Na, calculated 345.1243, 
observed 345.1244. 
 
 
5-Chloro-3-diethylamino-4-(4-methoxyphenyl)isothiazol-1,1-
dioxide (14a) 
 
A mixture of 4-chloroisothiazol-1,1-dioxide (11a) and 4,5-
dichloroisothiazolin-1,1-dioxide (12a) (3.23 g, ~10/1 mixture 
estimated by NMR) [see Supporting Information] was 
dissolved in dry acetone (10 mL) and potassium carbonate 
(1.35 g, 9.77 mmol) was added in one portion. The mixture was 
heated at reflux temperature under nitrogen for 8 days. The 
solvent was removed in vacuo and the residue was dissolved in 
DCM (15 mL) and neutralised with a 10% aqueous solution of 
hydrochloric acid. The aqueous layer was extracted with DCM 
(2 × 10 mL) and the combined organics layer were washed with 
water (2 × 10 mL), dried over Na2SO4 and filtered. The solvent 
was evaporated under reduced pressure to give the crude 
product as a sticky orange solid (2.21 g). Purification by gravity 
silica chromatography (PE/EtOAc: 2/1) afforded the isothiazol-
1,1-dioxide (13a) (1.24 g, data as per Supporting Information) 
and the 5-chloroisothiazol-1,1-dioxide (14a) as a yellow solid 
(0.22 g, m.p. = 123 – 125 °C). Data for (14a): 
1H NMR δ (500 MHz, CDCl3) 7.20 (2H, d, J = 8.5 Hz, ArH), 
7.03 (2H, d, J = 8.5 Hz, ArH), 3.87 (3H, s, OCH3), 3.65 (2H, q, 
J = 7.1 Hz, NCH2CH3), 3.15 (2H, q, J = 7.1 Hz, NCH2CH3), 
1.30 (3H, t, J = 7.1 Hz, NCH2CH3), 0.91 (3H, t, J = 7.1 Hz, 
NCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 160.69 (C=N), 160.42 (C-
OMe), 147.75 (C=C-Cl), 132.28 (C=C-Cl), 129.19 (CH, Ar), 
121.89 (C, Ar), 114.94 (CH, Ar), 55.38 (OCH3), 46.46 
(NCH2CH3), 43.72 (NCH2CH3), 14.10 (NCH2CH3), 11.92 
(NCH2CH3). 
IR υmax (cm
-1) 2976, 2840, 1624, 1604, 1564, 1508, 1306, 1248, 
1206, 1153, 1024, 884, 830, 802, 770. 
MS (m/z) (35Cl): 329.1 ([M + H]+). 
HRMS (m/z) (35Cl): [M + H]+ for C14H18ClN2O3S calculated 
329.0721 measured 329.0719. 
 
3-Diethylamino-5-methanesulfinyl-4-(4-
methoxyphenyl)isothiazol-1,1-dioxide (17a) 
 
3-Diethylamino-5-methanesulfanyl-4-(4-methoxyphenyl)-
isothiazol-1,1-dioxide (16a) (500 mg, 1.47 mmol) [see 
Supporting Information], was dissolved in dry DCM (10 mL) 
and m-CPBA (253 mg, 1.47 mmol) was added in one portion. 
The reaction was stirred at room temperature under nitrogen 
and monitored by thin layer chromatography. Further portions 
of m-CPBA were added to the mixture to complete the reaction 
(after 6 hours: 51 mg, 0.30 mmol; after 27 hours: 25 mg, 0.14 
mmol; after 50 hours: 25 mg, 0.14 mmol). After 54 hours, the 
m-chlorobenzoic acid precipitate was filtered off, and the 
filtrate was washed sequentially with a 20% aqueous NaHCO3 
solution (5 mL) and water (2 × 5 mL). The organic layer was 
separated, dried over anhydrous Na2SO4, and the solvent was 
removed under reduced pressure to give the crude product as a 
yellow solid which was purified by gravity silica 
chromatography (PE/ethyl acetate: gradient elution 2/1, 3/2, 
1/1) to yield the product as a yellow solid (350 mg, 67%, m.p. = 
167 – 169 °C). 
1H NMR δ (400 MHz, CDCl3) 7.41 (1H, bs, ArH), 7.15 (1H, 
bs, ArH), 7.02 (2H, bs, ArH), 3.87 (3H, s, OCH3), 3.66 (1H, 
dq, J = 13.6 and 7.1 Hz, NCH2CH3), 3.60 (1H, dq, J = 13.6 
and 7.1 Hz, NCH2CH3), 3.16 (3H, s, CH3SO), 3.11 (2H, q, J = 
7.1 Hz, NCH2CH3), 1.31 (3H, t, J = 7.1 Hz, NCH2CH3), 0.92 
(3H, t, J = 7.1 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 161.02 (C-OMe), 158.54 
(C=N), 155.81 (ArC=CSOCH3), 141.21 (ArC=CSOCH3), 
129.72 (CH, Ar), 128.66 (CH, Ar), 120.84 (C, Ar)), 114.91 
(CH, Ar), 114.56 (CH, Ar), 55.40 (OCH3), 47.26 (NCH2CH3), 
43.75 (NCH2CH3), 38.34 (CH3SO), 14.16 (NCH2CH3), 11.72 
(NCH2CH3). 
1H NMR δ (500 MHz, DMSO-D6) 7.54 (1H, bd, J = 8.2 Hz, 
ArH), 7.47 (1H, bd, J = 8.2 Hz, ArH), 7.09 (1H, bd, J = 8.2 Hz, 
ArH), 7.06 (1H, bd, J = 8.2 Hz, ArH), 3.81 (3H, s, OCH3), 3.53 
(2H, bq, J = 7.0 Hz, NCH2CH3), 3.08 (2H, bq, J = 7.0 Hz, 
NCH2CH3), 3.04 (3H, s, CH3SO), 1.20 (3H. t, J = 7.0 Hz, 
NCH2CH3), 0.83 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (125 MHz, DMSO-D6) 160.29 (C-OMe), 157.68 
(C=N), 154.79 (C=C), 139.89 (C=C), 129.98 (CH, Ar), 129.21 
(CH, Ar), 121.33 (C, Ar), 114.47 (CH, Ar), 114.28 (CH, Ar), 
55.30 (OCH3), 46.54 (NCH2CH3), 43.40 (NCH2CH3), 38.90 
(CH3SO), 13.60 (NCH2CH3), 11.47 (NCH2CH3). 
IR υmax (cm
-1) 2977, 1601, 1561, 1507, 1443, 1406, 1358, 1290, 
1247, 1205, 1146, 1066, 1021, 964, 829, 777, 733, 708. 
MS (m/z) 357.1 ([M + H]+), 713.2 ([2M + H]+), 735.2 ([2M + 
Na]+). 
HRMS (m/z): [M + NH4]
+ for C15H24N3O4S2 calculated 
374.1203 measured 374.1198. 
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1,2,3-Oxathiazolin-2-oxide (21) 
 
3-Diethylamino-1,2-thiazetin-1,1-dioxide (5a) (80 mg, 0.26 
mmol) and zinc chloride (260 μL of a 1M solution in diethyl 
ether, 0.26 mmol) were dissolved in toluene (2 mL). The whole 
was stirred under nitrogen and heated at reflux for a further 48 
hours. The solvent was removed in vacuo to give the crude 
product as a dark brown oil which was purified by gravity silica 
chromatography (hexane/EtOAc: 2/1) to give the product as a 
pure diastereoisomeric fraction (25 mg, 31 %) together with a 
second fraction as a mixture of diastereoisomers (10 mg, 13 %). 
 
Pure diastereoisomer: 
1H NMR δ (400 MHz, CDCl3) 7.60 (2H, d, J = 8.9 Hz, ArH), 
7.00 (2H, d, J = 8.9 Hz, ArH), 3.85 (3H, s, OCH3), 3.58 (2H, q, 
J = 7.1 Hz, NCH2CH3), 3.25 (1H, q, J = 7.1 Hz, NCH2CH3), 
3.24 (1H, q, J = 7.1 Hz, NCH2CH3), 1.30 (3H, t, J = 7.1 Hz, 
NCH2CH3), 0.83 (3H, t, J = 7.1 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 164.72 (Et2N-C=N), 161.23 (C-
OMe), 128.81 (CH, Ar), 125.25 (C, Ar), 115.01 (CH, Ar), 
114.55 (CN), 84.16 (C), 55.51 (OCH3), 45.47 (NCH2CH3), 
44.15 (NCH2CH3), 12.30 (NCH2CH3), 11.15 (NCH2CH3). 
IR υmax (cm
-1) 2975, 2938, 2838, 2055, 1595, 1514, 1261, 1183, 
1066, 1030. 
MS (m/z): 330.1 [M + Na]+, 637.2 [2M + Na]+. 
HRMS (m/z): [M + Na]+ for C14H17N3NaO3S calculated 
330.0883 measured 330.0879. 
 
Second diastereoisomer: 
1H NMR δ (500 MHz, CDCl3) 7.37 (2H, d, J = 8.8 Hz, ArH), 
6.99 (2H, d, J = 8.8 Hz, ArH), 3.84 (3H, s, OCH3), 3.73 (1H, 
dq, J = 13.6 and 7.1 Hz, NCH2CH3), 3.50 (1H, dq, J = 13.6 
and 7.1 Hz, NCH2CH3), 3.24 (1H, m, NCH2CH3), 3.18 (1H, 
dq, J = 14.4 and 7.1 Hz, NCH2CH3), 1.31 (3H, t, J = 7.1 Hz, 
NCH2CH3), 0.88 (3H, t, J = 7.1 Hz, NCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 166.34 (Et2N-C=N), 161.45 (C-
OMe), 127.52 (CH, Ar), 124.75 (C, Ar), 115.11 (CH, Ar), 
114.63 (CN), 81.68 (C), 55.53 (OCH3), 45.47 (NCH2CH3), 
44.75 (NCH2CH3), 12.35 (NCH2CH3), 11.23 (NCH2CH3). 
 
3-Diethylamino-3a-(4-methoxyphenyl)-6-phenylisothiazolino-
[4,5-d]isoxazolin-1,1-dioxide (22b) 
 
3-Diethylamino-4-(4-methoxyphenyl)-isothiazol-1,1-dioxide 
(13a) (100 mg; 0.34 mmol) and benzohydroximoyl chloride (53 
mg; 0.34 mmol) were suspended in dry diethyl ether (5 mL). 
Triethylamine (47 µL; 34 mg; 0.34 mmol) in dry diethyl ether 
(10 mL) was added drop-wise to the mixture over 5 – 6 hours. 
The mixture was stirred overnight (20 hours) under nitrogen, 
filtered, and the solvent evaporated under reduced pressure to 
give the crude product as a pale yellow solid (170 mg). It was 
purified by gravity silica chromatography (PE/EtOAc: 2/1) to 
give the product as a white fluffy solid (99 mg; 71%; m.p. = 78 
– 80 °C). 
1H NMR δ (400 MHz, CDCl3) 7.79 (2H, dd, J = 7.5 and 1.6 
Hz, ArH), 7.44 (3H, m, ArH), 7.36 (2H, d, J = 8.9 Hz, ArH), 
6.98 (2H, d, J = 8.9 Hz, ArH), 5.12 (1H, s, CH), 3.84 (3H, s, 
OCH3), 3.70 (1H, dq, J = 13.6 and 7.1 Hz, NCH2CH3), 3.43 
(1H, dq, J = 13.6 and 7.1 Hz, NCH2CH3), 3.27 (2H, m, 
NCH2CH3), 1.29 (3H, t, J = 7.1 Hz, NCH2CH3), 0.87 (3H, J = 
7.1 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 163.54 (C=N), 160.40 (C-
OMe), 152.52 (Ph-C=N-O), 131.13 (CH, Ph), 128.90 (CH, 
Ph), 128.86 (C, Ar), 127.55 (CH, Ph), 126.82 (C, Ph), 125.10 
(CH, Ar), 115.05 (CH, Ar), 99.16 (C (ring junction)), 79.27 
(CH (ring junction)), 55.44 (OCH3), 45.04 (NCH2CH3), 44.21 
(NCH2CH3), 12.76 (NCH2CH3), 11.38 (NCH2CH3). 
IR υmax (cm
-1) 2975, 1593, 1512, 1445, 1352, 1320, 1252, 1210, 
1177, 1136, 1096, 1031, 968, 947, 920, 890, 832, 773, 732. 
MS (m/z): 436.1 ([M + Na]+), 849.3 ([2M + Na]+), 1262.4 ([3M 
+ Na]+), 1675.6 ([4M + Na]+). 
HRMS (m/z): [M + Na]+ for C21H23N3NaO4S calculated 
436.1301 measured 436.1303. 
 
 
6a-Chloro-3-diethylamino-3a,6-di(4-methoxyphenyl)-
isothiazolino[4,5-d]isoxazolin-1,1-dioxide (22f) 
 
Using the procedure above for compound (22b), 5-chloro-3-
diethylamino-4-(4-methoxyphenyl)-isothiazol-1,1-dioxide 
(14a) (27 mg; 0.08 mmol), 4-methoxybenzohydroximoyl 
chloride (15 mg; 0.08 mmol) and triethylamine (12 μL; 8.7 mg; 
0.09 mmol) gave the crude product as a white oily solid (85 
mg). Purification by gravity silica chromatography (PE/EtOAc: 
3/1) afforded the product as a yellow oil (22 mg; 56%). 
1H NMR δ (500 MHz, CDCl3) 7.99 (2H, d, J = 8.8 Hz, ArH), 
7.57 (1H, bs, ArH), 7.00 (3H, bs, ArH), 6.93 (2H, d, J = 8.8 
Hz, ArH), 3.85 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.77 (1H, 
dq, J = 13.6 and 7.0 Hz, NCH2CH3), 3.40 (1H, dq, J = 14.2 
and 7.0 Hz, NCH2CH3), 3.36 (1H, dq, J = 13.6 and 7.0 Hz, 
NCH2CH3), 3.15 (1H, dq, J = 14.2 and 7.0 Hz, NCH2CH3), 
1.26 (3H, t, J = 7.0 Hz, NCH2CH3), 1.03 (3H, t, J = 7.0 Hz, 
NCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 162.94 (C-NEt2), 161.74 (C-
OMe), 160.94 (C-OMe), 154.81 (C=N), 130.42 (CH, Ar), 
127.95 (CH, Ar), 127.22 (CH, Ar), 123.70 (C, Ar), 117.36 (C, 
Ar), 114.51 (CH, Ar), 113.77 (CH, Ar), 101.01 (C (ring 
junction)), 90.36 (C-Cl (ring junction)), 55.36 (OCH3), 55.33 
(OCH3), 44.80 (NCH2CH3), 44.10 (NCH2CH3), 12.81 
(NCH2CH3), 11.17 (NCH2CH3). 
IR υmax (cm
-1) 2926, 2853, 1593, 1513, 1441, 1335, 1306, 1256, 
1180, 1162, 1028, 981, 963, 945, 918, 833, 810, 732. 
MS (m/z): 500.1 (35Cl) ([M + Na]+), 977.2 (35Cl) ([2M + Na]+). 
HRMS (35Cl) (m/z): [M + Na]+ for C22H24ClN3NaO5S 
calculated 500.1017 measured 500.1016. 
 
6a-Bromo-3-diethylamino-3a,6-di(4-methoxyphenyl)-
isothiazolino[4,5-d]isoxazolin-1,1-dioxide (22g) 
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Using the procedure above for compound (22b), 5-bromo-3-
diethylamino-4-(4-methoxyphenyl)-isothiazol-1,1-dioxide 
(15a) (102 mg; 0.27 mmol), 4-methoxybenzohydroximoyl 
chloride (51 mg; 0.27 mmol) and triethylamine (38 μL; 27 mg; 
0.27 mmol) gave a crude product which was purified by gravity 
silica chromatography (PE/EtOAc: 3/1) to give the product as 
an orange oil (77 mg; 54%). 
1H NMR δ (500 MHz, CDCl3) 8.05 (2H, d, J = 9.0 Hz, ArH), 
7.61 (1H, bs, ArH), 6.98 – 7.02 (3H, bs, ArH), 6.91 (2H, d, J = 
9.0 Hz, ArH), 3.84 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.76 
(1H, dq, J = 13.6 and 7.0 Hz, NCH2CH3), 3.41 (1H, dq, J = 
14.3 and 7.0 Hz, NCH2CH3), 3.35 (1H, dq, J = 13.6 and 7.0 
Hz, NCH2CH3), 3.13 (1H, dq, J = 14.3 and 7.0 Hz, NCH2CH3), 
1.25 (3H, t, J = 7.0 Hz, NCH2CH3), 1.03 (3H, t, J = 7.0 Hz, 
NCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 163.35 (N=C), 161.67 (C-
OMe), 160.88 (C-OMe), 155.44 (Ar-C=N), 130.80 (CH, Ar), 
128.17 (CH, Ar), 127.08 (CH, Ar), 125.36 (C, A), 117.60 (C, 
Ar), 114.33 (CH, Ar), 113.56 (CH, Ar), 101.21 (C (ring 
junction)), 81.77 (C-Br (ring junction)), 55.32 (OCH3), 55.29 
(OCH3), 44.77 (NCH2CH3), 44.05 (NCH2CH3), 12.82 
(NCH2CH3), 11.12 (NCH2CH3). 
MS (m/z): (79Br) 522.1 ([M + H]+), (81Br) 524.1 ([M + H]+), 
(79Br) 544.1 ([M + Na]+), (81Br) 546.1 ([M + Na]+). 
HRMS (79Br) (m/z): [M + H]+ for C22H25BrN3O5S calculated 
522.0693 measured 522.0693. 
 
3-Diethylamino-6a-methanesulfinyl-3a,6-di(4-methoxyphenyl)-
isothiazolino[4,5-d]isoxazolin-1,1-dioxide (22h) 
 
Using the procedure above for compound (22b), 3-
diethylamino-5-methanesulfinyl-4-(4-methoxyphenyl)-
isothiazol-1,1-dioxide (17a) (100 mg; 0.28 mmol), 4-
methoxybenzohydroximoyl chloride (52 mg; 0.28 mmol) and 
triethylamine (39 μL; 28 mg; 0.28 mmol) gave the crude 
product as a yellow oil (141 mg). Purification by gravity silica 
chromatography (hexane/EtOAc: 2/1) afforded the two 
diastereoisomers, one as a yellow solid (48 mg; 34%; m.p. = 
192 – 193 °C) and the other as a yellow solid (26 mg, 18%; 
m.p. 207 – 209 °C) in a ~2:1 ratio. 
Diastereoisomer 2: 
1H NMR δ (400 MHz, CDCl3) 8.02 (2H, d, J = 8.8 Hz, ArH), 
7.81 – 7.82 (1H, m, ArH), 7.12 – 7.14 (1H, m, ArH), 7.04 – 
7.07 (1H, m, ArH), 6.95 – 6.98 (3H, d, J = 8.8 Hz, and 
overlapped m, ArH), 3.85 (6H, s, 2 × OCH3), 3.78 (1H, dq, J = 
13.5 and 7.0 Hz, NCH2CH3), 3.43 (1H, dq, J = 14.3 and 7.0 
Hz, NCH2CH3), 3.36 (1H, dq, J = 13.5 and 7.0 Hz, NCH2CH3), 
3.11 (1H, dq, J = 14.3 and 7.0 Hz, NCH2CH3), 2.56 (3H, s, 
CH3SO) 1.29 (3H, t, J = 7.0 Hz, NCH2CH3), 1.05 (3H, t, J = 
7.0 Hz, NCH2CH3). 
13C NMR (100 MHz, CDCl3) 165.01 (C=N), 161.53 (C-OMe), 
161.15 (C-OMe), 151.70 (Ar-C=N-O), 133.05 (CH, Ar), 
129.41 (CH, Ar), 127.64 (CH, Ar), 121.41 (C, Ar), 119.56 (C, 
Ar), 114.51 (CH, Ar), 114.16 (CH, Ar), 113.76 (CH, Ar), 
102.49 (C-Ar (ring junction)), 95.34 (C-SOMe), 55.31 (OCH3), 
55.26 (OCH3), 45.16 (NCH2CH3), 43.94 (NCH2CH3), 35.41 
(SOCH3), 12.82 (NCH2CH3), 11.12 (NCH2CH3). 
IR υmax (cm
-1) 2935, 2840, 1591, 1512, 1440, 1333, 1305, 1254, 
1179, 1159, 1062, 1026, 978, 959, 936, 910, 831, 804, 792, 
728. 
MS (m/z): 528.1 [M + Na]+, 1033.3 [2M + Na]+, 1538.4 [3M + 
Na]+ 
HRMS (m/z): [M + Na]+ for C23H27N3NaO6S2 calculated 
528.1233 measured 528.1248. 
The structure of this compound (22h-D2) was confirmed by X-
ray crystallographic analysis.31 
 
Diastereoisomer 1: 
1H NMR δ (400 MHz, CDCl3) 8.23 (2H, d, J = 9.0 Hz, ArH), 
7.54 – 7.56 (1H, m, ArH), 7.49 – 7.51 (1H, m, ArH), 6.98 – 
6.70 (2H, m, ArH), 6.94 (2H, d, J = 9.0 Hz, ArH), 3.86 (3H, s, 
OCH3), 3.84 (3H, s, OCH3), 3.67 (1H, dq, J = 13.5 and 7.0 Hz, 
NCH2CH3), 3.33 (1H, dq, J = 14.3 and 7.0 Hz, NCH2CH3), 
3.28 (1H, dq, J = 13.5 and 7.0 Hz, NCH2CH3), 3.15 (1H, dq, J 
= 14.3 and 7.0 Hz, NCH2CH3), 2.33 (3H, s, CH3SO), 1.20 (3H, 
t, J = 7.0 Hz, NCH2CH3), 0.91 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 163.73 (C=N), 162.03 (C-
OMe), 161.07 (C-OMe), 154.67 (Ar-C=N-O), 132.22 (CH, 
Ar), 129.16 (CH, Ar), 126.71 (CH, Ar), 120.05 (C, Ar), 118.26 
(C, Ar), 115.02 (CH, Ar), 114.35 (CH, Ar), 113.79 (CH, Ar), 
100.03 (C), 93.85 (C), 55.43 (OCH3), 55.33 (OCH3), 45.45 
(NCH2CH3), 43.22 (NCH2CH3), 35.51 (CH3SO), 12.81 
(NCH2CH3), 11.08 (NCH2CH3). 
IR υmax (cm
-1) 2938, 2840, 1597, 1513, 1441, 1333, 1308, 1258, 
1183, 1158, 1061, 1032, 953, 912, 836. 
MS (m/z): 528.1 [M + Na]+, 1033.3 [2M + Na]+, 1538.4 [3M + 
Na]+. 
HRMS (m/z): [M + Na]+ for C23H27N3NaO6S2 calculated 
528.1233 measured 528.1243. 
The structure of this compound (22h-D1) was confirmed by X-
ray crystallographic analysis.31 
 
3-Diethylamino-6a-methanesulfonyl-3a,6-di(4-methoxyphenyl)-
isothiazolino[4,5-d]isoxazolin-1,1-dioxide (22i) 
 
Using the procedure above for compound (22b), 3-
diethylamino-5-methanesulfonyl-4-(4-methoxyphenyl)-
isothiazol-1,1-dioxide (6a) (101 mg; 0.27 mmol), 4-
methoxybenzohydroximoyl chloride (50 mg; 0.27 mmol) and 
triethylamine (38 μL; 28 mg; 0.27 mmol) gave the crude 
product as a yellow solid (159 mg). Purification by gravity 
silica chromatography (PE/EtOAc: 2/1) afforded the product as 
a white solid (96 mg; 68%; m.p. = 198 – 199 °C). 
1H NMR δ (400 MHz, CDCl3) 8.19 (2H, d, J = 9.1 Hz, ArH), 
7.87 (1H, dd, J = 8.8 and 2.6 Hz, ArH), 7.19 (1H, dd, J =  8.8 
and 2.6 Hz, ArH), 7.09 (1H, dd, J = 8.8 and 2.6 Hz, ArH), 6.98 
(1H, dd, J = 8.8 and 2.6 Hz, ArH), 6.93 (2H, d, J = 9.1 Hz, 
ArH), 3.87 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.80 (1H, dq, J 
= 13.6 and 7.0 Hz, NCH2CH3), 3.40 (1H, dq, J = 14.2 and 7.0 
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Hz, NCH2CH3), 3.31 (1H, dq, J = 13.6 and 7.0 Hz, NCH2CH3), 
2.99 (1H, dq, J =  14.2 and 7.0 Hz, NCH2CH3), 1.28 (3H, t, J = 
7.0 Hz, NCH2CH3), 1.13 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 163.73 (C=N), 161.76 (C-
OMe), 161.74 (C-OMe), 152.71 (Ar-C=N-O), 133.00 (CH, 
Ar), 129.99 (CH, Ar), 128.57 (CH, Ar), 120.03 (C, Ar), 118.67 
(C, Ar), 114.88 (CH, Ar), 113.42 (CH, Ar), 99.87 (C (ring 
junction)), 98.44 (C-SO2Me), 55.50 (OCH3), 55.28 (OCH3), 
45.21 (NCH2CH3), 43.94 (NCH2CH3), 42.76 (SO2CH3), 12.92 
(NCH2CH3), 11.02 (NCH2CH3). 
IR υmax (cm
-1): 2935, 1603, 1513, 1332, 1308, 1259, 1183, 
1169, 1161, 1144, 1026, 966, 835. 
MS (m/z): 544.1 [M + Na]+, 1065.3 [2M + Na]+. 
HRMS (m/z): [M + Na]+ for C23H27N3NaO7S2 calculated 
544.1183 measured 544.1197. 
The structure of this compound was confirmed by X-ray 
crystallographic analysis.31 
 
 
3-Diethylamino-6a-methanesulfinyl-3a-(4-
methoxyphenyl)isothiazolino[4,5-d]triazolin-1,1-dioxide (23a/b) 
 
3-Diethylamino-5-methanesulfinyl-4-(4-methoxyphenyl)-
isothiazol-1,1-dioxide (17a) (200 mg, 0.56 mmol) was 
dissolved in dry acetonitrile (10 mL), and sodium azide (38 mg, 
0.58 mmol) was added to the mixture. The whole was stirred at 
RT under nitrogen, and the reaction was monitored by TLC. 
After 30 hours, the solvent was removed in vacuo to give the 
crude product as a yellow solid (257 mg). Purification by flash 
silica chromatography (PE/EtOAc: gradient elution 1/1, 1/2, 
1/4) gave the product as two separable diastereoisomers (23a) 
(50 mg, 22%, m.p. = 133 °C) and (23b) (60 mg, 27%, m.p. = 
142 – 143 °C). 
Diastereoisomer (23a): 
1H NMR δ (500 MHz, CDCl3) 12.16 (1H, bs, NH), 7.44 – 7.46 
(1H, m, ArH), 7.39 – 7.41 (1H, m, ArH), 6.97 (2H, d, J = 8.7 
Hz, ArH), 3.85 (3H, s, OCH3), 3.74 (1H, dq, J = 14.5 and 7.0 
Hz, NCH2CH3), 3.49 (1H, dq, J = 13.5 and 7.0 Hz, NCH2CH3), 
3.39 (1H, dq, J = 13.5 and 7.0 Hz, NCH2CH3), 3.37 (1H, dq, J 
= 14.5 and 7.0 Hz, NCH2CH3), 2.11 (3H, s, CH3SO), 1.17 (3H, 
t, J = 7.0 Hz, NCH2CH3), 0.65 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (125 MHz, CDCl3): 161.66 (C=N), 160.90 (C-
OMe), 128.85 (CH, Ar), 128.16 (CH, Ar), 121.67 (C, Ar), 
115.03 (CH, Ar), 98.90 (C), 96.43 (C-SOMe), 55.43 (OCH3), 
45.56 (NCH2CH3), 43.83 (NCH2CH3), 33.27 (CH3SO), 12.51 
(NCH2CH3), 11.28 (NCH2CH3). 
1H NMR δ (400 MHz, DMSO-D6) 13.78 (1H, bs, NH), 7.43 – 
7.45 (1H, m, ArH), 7.19 – 7.07 (3H, m, ArH), 3.78 (3H, s, 
OCH3), 3.67 (1H, dq, J = 14.3 and 7.0 Hz, NCH2CH3), 3.43 – 
3.32 (3H, m, NCH2CH3), 1.99 (3H, s, CH3SO), 1.07 (3H, t, J = 
7.0 Hz, NCH2CH3), 0.56 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (100 MHz, DMSO-D6) 161.95 (C=N), 160.72 (C-
OMe), 129.02 (CH, Ar), 128.72 (CH, Ar), 121.78 (C, Ar), 
115.42 (CH, Ar), 98.50 (C), 97.02 (C-SOMe), 55.87 (OCH3), 
45.44 (NCH2CH3), 43.93 (NCH2CH3), 33.46 (CH3SO), 12.74 
(NCH2CH3), 11.56 (NCH2CH3). 
IR υmax (cm
-1) 3080, 2964, 2929, 2853, 1590, 1513, 1327, 1304, 
1257, 1157, 1131, 1100, 1029, 836. 
MS (m/z): 422.1 [M + Na]+, 821.2 [2M + Na]+. 
HRMS (m/z): [M + NH4]
+ for C15H25N6O4S2 calculated 
417.1373 measured 417.1367. 
 
Diastereoisomer (23b): 
1H NMR δ (400 MHz, CDCl3) 10.64 (1H, bs, NH), 7.35 (1H, d, 
J = 8.6 Hz, ArH), 7.16 (1H, d, J = 8.6 Hz, ArH), 7.02 (1H, d, J 
= 8.6 Hz, ArH), 6.99 (1H, d, J = 8.6 Hz, ArH), 3.86 (3H, s, 
OCH3), 3.67 (1H, dq, J = 13.5 and 7.0 Hz, NCH2CH3), 3.57 
(1H, dq, J = 14.3 and 7.0 Hz, NCH2CH3), 3.50 (1H, dq, J = 
14.3 and 7.0 Hz, NCH2CH3), 3.39 (1H, dq, J = 13.5 and 7.0 
Hz, NCH2CH3), 2.87 (3H, s, CH3SO), 1.27 (3H, t, J = 7.0 Hz, 
NCH2CH3), 0.90 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (100 MHz, CDCl3) 162.59 (C=N), 160.92 (C-
OMe), 129.67 (CH, Ar), 127.82 (CH, Ar), 121.71 (C, Ar), 
114.95 (CH, Ar), 114.40 (CH, Ar), 102.77 (C), 95.66 (C-
SOMe), 55.35 (OCH3), 45.16 (NCH2CH3), 44.42 (NCH2CH3), 
34.72 (CH3SO), 12.87 (NCH2CH3), 11.25 (NCH2CH3). 
1H NMR δ (400 MHz, DMSO-D6) 13.22 (1H, bs, NH), 7.21 
(1H, d, J = 8.7 Hz, ArH), 7.10 (1H, d, J = 8.7 Hz, ArH), 7.06-
7.02 (2H, m, ArH), 3.79 (3H, s, OCH3), 3.54-3.44 (3H, m, 
NCH2CH3), 3.35 (1H, m, NCH2CH3), 2.73 (3H, s, CH3SO), 
1.12 (3H, t, J = 7.0 Hz, NCH2CH3), 0.77 (3H, t, J = 7.0 Hz, 
NCH2CH3). 
13C NMR δ (100 MHz, DMSO-D6) 163.03 (C=N), 160.75 (C-
OMe), 130.12 (CH, Ar), 128.25 (CH, Ar), 122.43 (C, Ar), 
114.92 (CH, Ar), 114.88 (CH, Ar), 101.35 (C-Ar), 96.21 (C-
SOMe), 55.82 (OCH3), 45.17 (NCH2CH3), 44.40 (NCH2CH3), 
34.10 (CH3SO), 13.10 (NCH2CH3), 11.53 (NCH2CH3). 
IR υmax (cm
-1) 3118, 3017, 2976, 2935, 2898, 1604, 1510, 1424, 
1316, 1299, 1258, 1244, 1165, 1153, 1128, 1045, 1025, 1002, 
957, 911, 836. 
MS (m/z): 422.1 [M + Na]+, 821.2 [2M + Na]+. 
HRMS (m/z): [M + NH4]
+ for C15H25N6O4S2 calculated 
417.1373 measured 417.1379. 
The structure of this compound was confirmed by X-ray 
crystallographic analysis.31 
 
3-Diethylamino-4,6-diphenyl-3a-(4-
methoxyphenyl)isothiazolino[4,5-d]pyrazolin-1,1-dioxide (24) 
 
3-Diethylamino-4-(4-methoxyphenyl)-isothiazol-1,1-dioxide 
(13a) (100 mg, 0.34 mmol) and α-chlorobenzaldehyde 
phenylhydrazone (117 mg, 0.51 mmol) were suspended in dry 
ether (5 mL). Triethylamine (71 μL, 51 mg, 0.51 mmol) in dry 
ether (15 mL) was added drop-wise to the mixture over 4 to 5 
hours. The whole was stirred under nitrogen at RT for 72 hours 
and then at reflux for 22 hours. The mixture was filtered, and 
the solvent evaporated to give the crude product as a pale 
brown oil which was purified by gravity silica chromatography 
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(PE/EtOAc: gradient elution 3/1, 2/1) to give the product as a 
yellow solid (68 mg, 41 %, m.p. = 210 – 211 °C). 
1H NMR δ (500 MHz, CDCl3) 7.75 – 7.85 (2H, m, CH, Ph), 
7.50 – 7.52 (2H, m, CH, Ph), 7.30 – 7.40 (8H, m, CH, Ph), 
7.00 (2H, d, J = 9.00 Hz, CH, Ar), 4.90 (1H, s, CH (ring 
junction)), 3.82 (3H, s, OCH3), 3.56 (1H, dq, J = 13.6 and 7.0 
Hz, NCH2CH3), 3.01 (1H, dq, J = 13.6 and 7.0 Hz, NCH2CH3), 
2.96 (1H, dq, J = 14.2 and 7.0 Hz, NCH2CH3), 1.99 (1H, dq, J 
= 14.2 and 7.0 Hz, NCH2CH3), 0.78 (3H, t, J = 7.0 Hz, 
NCH2CH3), 0.33 (3H, t, J = 7.0 Hz, NCH2CH3). 
13C NMR δ (125 MHz, CDCl3) 162.11 (C=N), 159.87 (C-
OMe), 144.26 (C), 143.01 (C), 132.02 (C), 130.23 (C), 129.76 
(CH, Ar), 129.61 (CH, Ar), 129.13 (CH, Ar), 128.92 (CH, Ar), 
128.74 (CH, Ar), 126.49 (CH, Ar), 125.98 (C), 115.05 (CH, 
Ar), 85.19 (C (ring junction)), 82.84 (CH (ring junction)), 
55.43 (OCH3), 45.28 (NCH2CH3), 44.16 (NCH2CH3), 11.24 
(NCH2CH3), 10.51 (NCH2CH3). 
IR υmax (cm
-1) 2979, 1574, 1508, 1492, 1444, 1357, 1308, 1250, 
1171, 1133, 1096, 1031, 977, 911, 894, 836, 781, 755, 729, 
705, 692. 
MS (m/z): 511.2 [M + Na]+, 999.4 [2M + Na]+. 
HRMS (m/z): [M + Na]+ for C27H28N4NaO3S calculated 
511.1774 measured 511.1778. 
The structure of this compound was confirmed by X-ray 
crystallographic analysis.31 
 
Conclusions 
 
Our initial aim was to use Clerici’s thiazete 1,1-dioxide (5a) as 
a novel substrate for 1,3-dipolar and cyclopropenone based 
cycloadditions. We have shown, disappointingly, that the 
thiazete 1,1-dioxide (5a) is not reactive towards 1,3-dipoles or 
cyclopropenones, in marked contrast to the 1-azetine system, 
but that it does undergo rearrangement into the previously 
unreported 1,2,3-oxathiazolin-2-oxide (21). However, we have 
produced sixteen new isothiazoloisoxazoles and four new 
isothiazole 1,1-dioxides building upon the route used to access 
the thiazete 1,1-dioxide (5a). We have established that the 
previously unreported sulfoxide substituted isothiazole 1,1-
dioxide (17a) produced a new isothiazolotriazole upon reaction 
with sodium azide, and we suggest that this offers some 
mechanistic insight into the conversion of the corresponding 
sulfone substituted isothiazole 1,1-dioxide (6a) into the thiazete 
1,1-dioxide (5a). We have also produced one new 
isothiazolopyrazole, establishing the reactivity of isothiazole 
1,1-dioxides towards nitrilimines, an aspect that we aim to 
explore further. The structure of this isothiazolopyrazole 
together with that of the isothiazolotriazole and four of the 
isothiazoloisoxazoles were confirmed, for the first time, by X-
ray crystallographic studies. Four of our new 
isothiazoloisoxazoles and the isothiazolotriazole showed 
restricted rotation of the sterically hindered bridgehead 
substituents. A further subset of four of our new 
isothiazoloisoxazoles showed promising low μM activity 
against a human breast carcinoma cell line and we are currently 
exploring this aspect of our findings further. 
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